Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
about
Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure.Roles of Na⁺/H⁺ exchanger type 1 and intracellular pH in angiotensin II-induced reactive oxygen species generation and podocyte apoptosis.Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot studyOxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive ratsCytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive ratsInvolvement of cytochrome P-450 1B1 in renal dysfunction, injury, and inflammation associated with angiotensin II-induced hypertension in rats.Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.Pressure induces intracellular calcium changes in juxtaglomerular cells in perfused afferent arteriolesN-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibitionEffects of Cilnidipine on Heart Rate and Uric Acid Metabolism in Patients With Essential Hypertension.1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats.Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes.Effects of Cilnidipine, an L/N-Type Calcium Channel Blocker, on Carotid Atherosclerosis in Japanese Post-Stroke Hypertensive Patients: Results from the CA-ATTEND Study.Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
P2860
Q27347280-FBC52D19-C41D-4692-9D08-647A38641279Q31122004-E5C442BC-400A-49C9-A53A-B82822C51BF2Q33603428-9DBA7CC7-C332-428D-9376-3382F71A45AAQ34388248-F07B8F88-D219-41B4-985D-7977906F55AEQ35105331-17416CE4-8806-40AA-847A-54666F9812BBQ35787438-60D36D76-BEF2-4F69-9F3B-9949FB18671EQ35842921-465DA5F4-6ADE-41DC-82FD-B6341AA619B0Q35951398-25DA4C1D-0F4D-419A-8668-438B2B52A6B4Q36236587-5BF70FC4-67CC-4C14-BA1A-609FEC43E96AQ37629261-5F032A28-81E4-43BE-93F0-0FDC1D2E4D43Q38125687-02FA2225-AB85-4319-86F8-C21136616163Q46592218-F56DC423-E794-4C52-9CEF-22D5E3E455D9Q46736252-714EF074-F1E4-49C2-BF8C-C650847B9912Q49963057-5B1AE299-B503-4B09-9058-C2BA65D7ACC9Q51742319-DEA1697F-DBFF-4661-8E60-2962E09926B7
P2860
Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cilnidipine suppresses podocyt ...... e calcium channel in podocyte.
@ast
Cilnidipine suppresses podocyt ...... e calcium channel in podocyte.
@en
type
label
Cilnidipine suppresses podocyt ...... e calcium channel in podocyte.
@ast
Cilnidipine suppresses podocyt ...... e calcium channel in podocyte.
@en
prefLabel
Cilnidipine suppresses podocyt ...... e calcium channel in podocyte.
@ast
Cilnidipine suppresses podocyt ...... e calcium channel in podocyte.
@en
P2093
P2860
P1476
Cilnidipine suppresses podocyt ...... pe calcium channel in podocyte
@en
P2093
Akira Nishiyama
Daisuke Nakano
Diah Suwarni
Hirofumi Hitomi
Hiroyuki Ohsaki
Katsuhiko Asanuma
Masakazu Kohno
Naro Ohashi
Takahisa Noma
Toshiro Fujita
P2860
P304
P356
10.1097/HJH.0B013E328336ADE3
P577
2010-05-01T00:00:00Z